Business Context and Reporting Period
Company: Icecure Medical Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of July 2025 (Report No. 4)
Date: July 25, 2025
This filing reports the issuance of a press release regarding the presentation of updated positive clinical data for the Company's ProSense® cryoablation system at the Japanese Breast Cancer Society Conference.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K serves solely to disseminate clinical data updates and does not contain financial statements or performance metrics.
Material Changes
No material financial changes versus the prior comparable period are reported in this document. The material update concerns clinical outcomes, specifically a reported 99% recurrence-free rate with cryoablation for breast cancer patients.
Guidance, Outlook, and Risks
Management Commentary: The Company highlighted the presentation of updated clinical data demonstrating a 99% recurrence-free rate using its ProSense® technology.
Forward-Looking Statements: The filing incorporates by reference the "Forward-Looking Statements" section from the attached press release (Exhibit 99.1), though the specific text of these statements is not included in the provided content.
Risks and Contingencies: No specific risks or contingencies are detailed in the body of this filing text.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) to review the specific clinical study details and the "Forward-Looking Statements" disclaimer.
- Confirm the sample size and methodology behind the reported 99% recurrence-free rate.
- Check subsequent filings for any financial impact or commercialization updates resulting from this clinical data presentation.